Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
In Part 2, Maureen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, dive deeper into Navigating Health Equity in 2024, focusing on the significance of accreditations in addressing health disparities and promoting health equity, highlighting programs for achieving accreditation and advocating for the integration of social determinants of health (SDOH) and health equity practices within pharmacy and health care.
2024 will be the first full year in which health systems will be held accountable by The Joint Commission (TJC) for performance on their National Patient Safety Goal to improve health care equity. Marueen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, Healthcare Administration Graduate Intern at Stanford Health Care share their unique perspectives in this AJMC article.
Patients already look beyond their prescription benefits for ways to pay. As cost-sharing rises and payer formulary controls and exclusions expand, patient demand for new solutions will grow. PRECISIONvalue Chief Medical Officer Dominic Galante discusses the future of access management in this Access90 video.
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video.
Cynthia Miller shares her view on how a focus on prevention can improve health outcomes and contain costs in The Pharma Letter.
Download the latest IRA Special Edition Update -- Medicare Drug Price Negotiation: First 10 Drugs Announced. These drugs accounted for $50.5 billion in Medicare Part D spending from June 2022 to May 2023. So what happens next?
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
